Objective. An unconventional population of CD4+ signaling lymphocytic activation molecule family member 7-positive (SLAMF7+) cytotoxic effector memory T (T EM ) cells (CD4+ cytotoxic T lymphocytes [CTLs]) has been linked causally to IgG4-related disease (IgG4-RD). Glucocorticoids represent the first-line therapeutic approach in patients with IgG4-RD, but their mechanism of action in this specific condition remains unknown. We undertook this study to determine the impact of glucocorticoids on CD4+ CTLs in IgG4-RD.
Objective. An unconventional population of CD4+ signaling lymphocytic activation molecule family member 7-positive (SLAMF7+) cytotoxic effector memory T (T EM ) cells (CD4+ cytotoxic T lymphocytes [CTLs] ) has been linked causally to IgG4-related disease (IgG4-RD). Glucocorticoids represent the first-line therapeutic approach in patients with IgG4-RD, but their mechanism of action in this specific condition remains unknown. We undertook this study to determine the impact of glucocorticoids on CD4+ CTLs in IgG4-RD.
Methods. Expression of CD8a, granzyme A, perforin, and SLAMF7 within the effector memory compartment of CD45RO+ (T EM ) and CD45RA+ effector memory T (T EMRA ) CD4+ cells was quantified by flow cytometry in 18 patients with active IgG4-RD, both at baseline and after 6 months of glucocorticoid treatment. Eighteen healthy subjects were studied as controls. Next-generation sequencing of the T cell receptor a-and b-chain gene was performed on circulating CD4+ CTLs from patients with IgG4-RD before and after treatment and in affected tissues.
Results. Circulating CD4+ T EM and T EMRA cells were not expanded in IgG4-RD patients compared to healthy controls. CD4+SLAMF7+ T EM cells (but not T EMRA cells) were significantly increased among IgG4-RD patients. Within CD4+SLAMF7+ T EM cells, CD8aÀ cells but not CD8a low cells were elevated in IgG4-RD patients. The same dominant clones of CD8aÀCD4+SLAMF7+ T EM cells found in peripheral blood were also identified in affected tissue. CD8aÀ and CD8a low CD4+SLAMF7+ T EM cells both expressed cytolytic molecules. Clonally expanded CD8aÀ but not CD8a low CD4+SLAMF7+ T EM cells decreased following glucocorticoid-induced disease remission.
Conclusion. A subset of CD8aÀCD4+SLAMF7+ cytotoxic T EM cells is oligoclonally expanded in patients with active IgG4-RD. This T EM cell population contracts following glucocorticoid-induced remission. Further characterization of this cell population may provide prognostic information and targets for therapeutic intervention.
IgG4-related disease (IgG4-RD) is an increasingly recognized immune-mediated condition that includes a variety of clinical manifestations previously regarded as unique, single-organ disorders unrelated to each other. The clinical manifestations of IgG4-RD include autoimmune pancreatitis, retroperitoneal fibrosis, chronic sialadenitis, and hypertrophic pachymeningitis, among others (1, 2) . IgG4-RD is also commonly referred to as a fibroinflammatory disorder characterized by tumefactive lesions, frequent elevation of serum IgG4 levels, and tissue fibrosis (1) . Glucocorticoids represent the treatment of choice to induce IgG4-RD remission, but their effect on the cells orchestrating the disease remains unknown (1) . Likewise, the profibrotic mechanisms driving IgG4-RD remain poorly elucidated.
Recently, the accepted view of IgG4-RD as a Th2-mediated disorder has been questioned by the identification of an unusual population of clonally expanded CD4+ cytotoxic T lymphocytes (CTLs) that accumulate within affected tissues (3) (4) (5) . In contrast to the lack of correlation with Th2 lymphocytes, CD4+ CTLs appear linked to IgG4-RD activity because they are increased in the peripheral blood of subjects with active disease and decrease following rituximab-induced remission despite their lack of CD20 expression (3) (4) (5) (6) (7) (8) . They express CD8a/ a homodimers in addition to CD4 and share several features with CD8+ CTLs (which express CD8a/b heterodimers as well as CD8a/a homodimers), including the production of cytolytic molecules (4, 9) . Moreover, CD4+ CTLs in patients with IgG4-RD secrete profibrotic cytokines (such as interleukin-1b, interferon-c, and transforming growth factor b) and express signaling lymphocytic activation molecule family member 7 (SLAMF7), a surface antigen implicated in homotypic interactions with activated B cells and disease immunopathogenesis (4, 10) . Thus, because CD4+ CTLs have the potential both to stimulate fibroblast activation and to interact with antigenpresenting B cells, these cells may play a central role in the pathogenesis of IgG4-RD (1) .
To better clarify the mechanisms of action of glucocorticoids in IgG4-RD and the pathogenic relevance of CD4+ CTLs, we aim to describe the effects of corticosteroid treatment on CD4+ CTLs. Glucocorticoids offer a unique vantage point for observing variations of putatively pathogenic T lymphocytes, because it has been shown that they do not drastically perturb B and T cell counts in the peripheral blood (11, 12) . On the other hand, rituximab reduces the circulating levels of activated CD4+ T lymphocytes in a global manner by abrogating the survival and differentiation signals provided by naive B cells (13, 14) . In the present work, we also identify a population of CD8aÀCD4+SLAMF7+ effector memory T (T EM ) cells-corresponding to a subset of CD4+ CTLs-that are oligoclonally expanded in the peripheral blood of patients with active IgG4-RD and whose numbers contract with disease remission.
PATIENTS AND METHODS
Patients. Eighteen consecutive patients with active, untreated IgG4-RD who had been referred to the San Raffaele Scientific Institute were included in this observational prospective study (15) . IgG4-RD was diagnosed according to the consensus statement on the pathology of IgG4-RD and the comprehensive diagnostic criteria for IgG4-RD (16, 17) . Patients with isolated pancreatic involvement who did not undergo pancreatic biopsy were diagnosed as having definite IgG4-RD according to the international consensus diagnostic criteria for autoimmune pancreatitis (18) . All patients were initially treated with prednisone (0.6-1 mg/kg) for 1 month; prednisone was gradually tapered and withdrawn after 6 months in accordance with international guidelines (12) . Blood for serologic and immunologic studies and clinical correlations was obtained at baseline and 6 months after the institution of glucocorticoid treatment. Eighteen healthy age-and sex-matched subjects served as controls. All patients gave written informed consent for the analyses performed. The study was conducted according to the Declaration of Helsinki and approved by the Ethics Committee of the San Raffaele Scientific Institute.
Disease activity. IgG4-RD activity was assessed by means of the IgG4-RD responder index (RI). Active disease was defined by an IgG4-RD RI ≥3. Disease remission was defined by an IgG4-RD RI <3. A reduction in the IgG4-RD RI of ≥2 points still with a total score ≥3 was considered a partial response to glucocorticoid treatment (19) .
Flow cytometry. Peripheral blood mononuclear cells were isolated from patients with IgG4-RD and healthy controls by Ficoll density-gradient centrifugation (GE Healthcare), resuspended in fetal bovine serum (FBS) containing 10% DMSO, and cryopreserved. For T cell surface staining, cells were stained at 4°C for 30 minutes in staining buffer containing optimized concentrations of the following fluorochrome-conjugated anti-human antibodies (purchased from BioLegend unless otherwise specified): phycoerythrin (PE)-conjugated anti-CD4 (clone RPA-T4; BD Biosciences), PE-Cy7-conjugated anti-CD4 (clone OKT4), fluorescein isothiocyanate (FITC)-conjugated anti-CD8a (clone HIT8a; BD Biosciences), PE-conjugated anti-CD8a (clone SK1), allophycocyanin (APC)-Cy7-conjugated anti-CD27 (clone 0323), BV510-conjugated anti-CD27 (clone MT271), Pacific Blue (PB)-conjugated anti-CD45RO (clone UCHLa), BV605-conjugated anti-CD45RA (clone Hl100; BD Biosciences), PE-Cy7-conjugated anti-CD62L (clone DREG-56), APC-conjugated anti-CD319/SLAMF7 (clone 162.1), and Alexa Fluor 647-conjugated anti-CD319/ SLAMF7 (clone 235614; BD Biosciences).
Viable cells were identified among those negative for 7-aminoactinomycin D Viability Staining Solution (BioLegend). For intracellular staining of granzyme A and perforin on T cells using PE-conjugated anti-granzyme A (clone CB9d) and FITCconjugated antiperforin (clone dG9), cells were fixed and permeabilized with a BD Cytofix/Cytoperm kit according to the instructions of the manufacturer (BD Biosciences) and then stained in permeabilization buffer at 4°C for 30 For plasmablast staining, 10-color flow cytometry (Navios cytometer; Beckman Coulter) was readily performed on EDTAtreated fresh whole blood samples using a lyse-no-wash technique (ammonium chloride) and the following panel of directly conjugated antibodies: FITC-conjugated anti-CD3, PE-conjugated anti-CD56, energy-coupled dye-conjugated anti-CD4, PC5.5-conjugated anti-CD138, PC7-conjugated anti-CD27, APC-conjugated anti-CD20, Alexa Fluor 700-conjugated anti-CD19, Alexa Fluor 750-conjugated anti-CD38, PB-conjugated anti-CD8, and Krome Orange-conjugated anti-CD45 (all from Beckman Coulter). Plasmablasts were identified within the lymphocyte gate as CD19+ CD20ÀCD27+CD38 +/bright cells. Cell sorting and immunofluorescence. Using a Beckman Coulter MoFlo XDP instrument, CD4+CD45RO+CD27 low CD62L low CD319/SLAMF7+CD8À cells were sorted from 2 patients with IgG4-RD at the time of diagnosis (patients 1 and 5) and from 1 patient after 6 months of glucocorticoids (patient 1). Cells were cultured overnight in Dulbecco's modified Eagle's medium/10% FBS, L-glutamine, and antibiotics on Lab-Tek Chamber Slides (Thermo Fisher) previously coated with poly-L-lysine (Sigma-Aldrich). Cells were fixed in 4% paraformaldehyde for 10 minutes at room temperature followed by incubation for 1 hour with phosphate buffered saline (PBS) containing 0.1% Triton X-100, 10% serum, and 3% bovine serum albumin (BSA) (blocking solution). For granzyme staining, cells were incubated with mouse anti-human granzyme A monoclonal antibody (Chemicon) overnight at 4°C in PBS/10% BSA followed by an Alexa Fluor 488-conjugated goat anti-mouse secondary antibody (Invitrogen) and Hoechst 33342 Solution (Thermo Fisher) (for nuclear staining). Unrelated mouse IgG antibody was used in parallel as isotype control. Images were captured using a PerkinElmer Ultraview ESR Laser Scanning Confocal microscope. Linear adjustments of the images were done using Adobe Photoshop CS4.
Next-generation sequencing. Total RNA was extracted from formalin-fixed paraffin-embedded (FFPE) tissues from patient 1 (pancreas) and patient 5 (lacrimal gland and lungs) (Pathology Unit of San Raffaele Institute) using a Maxwell 16 LEV RNA FFPE kit according to the protocol of the manufacturer (Promega). RNA extraction from sorted CD8aÀCD4+ SLAMF7+ CTLs was performed with a PicoPure RNA Isolation Kit (Thermo Fisher). RNA concentration was assessed with a Qubit 2.0 Fluorometer (Thermo Fisher) using a Qubit RNA Assay kit (Thermo Fisher). RNA integrity (the RNA integrity number) was evaluated on an Agilent 2100 Bioanalyzer with an RNA 6000 Nano kit (Agilent).
High-throughput sequencing of the T cell receptor (TCR) a-and b-chain repertoire was performed by using a modified rapid amplification of complementary DNA (cDNA) ends polymerase chain reaction (PCR) protocol (20, 21) . TCR-specific cDNA was reverse transcribed using the SmartScribe enzyme (Takara Bio) in the presence of biotinylated primers specific for the constant a-and b-chain genes and in the presence of a barcoded (5-bp) template switching primer. Enrichment of the TCR-specific biotinylated cDNA molecules was obtained using streptavidin magnetic beads (Dynabeads; Life Technologies). Upon magnetic capture, TCR-specific cDNA was washed and resuspended in 10 ll water. One microliter of cDNA and 1 ll of the first PCR product were used as input material for the first and second exponential PCRs, respectively. In the first exponential PCR, primers specific for the constant a-and b-chain gene and for the template switching sequence were used. In the second exponential PCR, fusion primers harboring Illumina MiSeq sequencing adaptors were added. In particular, a barcoded (10-bp) fusion primer specific for the constant TCR genes was used to tag each individual sample. PCR amplicons were purified using AmPure beads (Beckman Coulter).
Library quantification was performed with a Qubit 2.0 Fluorometer using a Qubit double-stranded DNA HS kit (Thermo Fisher), and the fragment length distribution was assessed on an Agilent 2100 Bioanalyzer with a High Sensitivity DNA kit (Agilent). Libraries were sequenced in paired-end mode (300 bp read 1 plus 150 bp read 2) on a MiSeq platform using MiSeq version 3 600-cycle reagents (Illumina). After demultiplexing of the sequencing results, analysis of the third complementarity-determining region (CDR3) clonotypes was carried out using MiTCR software (22, 23) .
Statistical analysis. Statistical analysis was performed with GraphPad Prism software, version 6.0. The population distributions were analyzed for normality with the D'AgostinoPearson normality test. Comparisons between the different populations were performed with paired and unpaired MannWhitney and Wilcoxon correction tests. Correlation studies were performed with Pearson or Spearman correlation tests. Linear regression analyses were performed, and their results are expressed as P values. Results are presented as the median and range unless otherwise specified. P values less than 0.05 were considered significant.
RESULTS
Clinical, serologic, and immunologic features in the cohort of patients with IgG4-RD. Eighteen patients (11 men and 7 women) with a mean age of 64 years (range 47-83 years) were included in the study (Table 1 ). All patients had definite IgG4-RD based on the 2012 consensus statement on the pathology of IgG4-RD (16) . The pancreas was the most commonly affected organ (10 cases), followed by lymph nodes (6 cases), the biliary tree (3 cases), the aorta (3 cases), and the lacrimal glands (2 cases). The parotid glands, lung, and submandibular glands were involved in 1 case each. Eight patients (44%) had ≥2 organs involved by IgG4-RD. All patients had active IgG4-RD as defined by a mean IgG4-RD RI of 8 (range 6-15; normal <3). The mean levels of serum IgG4 and circulating plasmablasts were 423 mg/dl (range 156-1,360 mg/dl; normal <135 mg/dl) and 5,781 cells/ml (range 140-40,840 cells/ml; normal 0-653 cells/ml), respectively. Serum IgG4 levels were elevated in all patients. Circulating plasmablasts were elevated in 16 patients (89%).
CD4+ T EM and T EMRA cells are not expanded in treatment-naive patients with newly diagnosed, active IgG4-RD. In patients with IgG4-RD, CD4+ CTLs have been identified following the observation of expanded circulating CD4+CD45RO+CD27 low CD62L
low T EM cells during active disease (4) . Therefore, to study CD4+ CTLs, we first performed flow cytometry analysis on CD27 low CD62L low cells within the CD4+CD45RO+ memory T cell compartment. Circulating CD4+ T EM cells were not increased in our cohort of patients with active, untreated IgG4-RD compared to age-and sex-matched healthy individuals. In particular, the absolute counts of circulating CD4+ T EM cells in IgG4-RD patients and healthy subjects were a median of 85,830 cells/ml (range 18,462-239,643 cells/ml) and 82,385 cells/ml (range 32,832-194,000 cells/ ml), respectively (P > 0.05). CD4+ T EM cells in IgG4-RD patients and controls represented a median of 20% (range 10.4-64.7%) and 18% (range 10.8-46.2%), respectively, of total CD4+CD45RO+ memory T cells (P > 0.05) (Figures 1A and B) . Absolute counts of CD4+ T EM cells did not correlate with the number of organs involved by IgG4-RD, the IgG4-RD RI, serum IgG4 levels, or numbers of circulating plasmablasts (data not shown).
CD4+ CTLs were described originally in the setting of chronic viral infections as CD27 low CD62L low CD4+ CD45RA+ effector memory T (T EMRA ) cells that acquire a cytolytic gene program after down-regulation of the transcription factor Th-inducing POZ/Kruppel-like factor and up-regulation of eomesodermin and RUNX-3 (24, 25) . Therefore, we also examined the expansion of CD27 low CD62L low cells within the CD4+CD45RA+ (T EMRA ) cell compartment by flow cytometry, but we did not identify significant differences between IgG4-RD patients and healthy subjects (P > 0.05) (Figures 1C and D) .
Expansion of CD8aÀCD4+SLAMF7+ T EM cells in peripheral blood of patients with active, untreated IgG4-RD. CD4+ CTLs in IgG4-RD have been described as SLAMF7-expressing cells within the CD4+ T EM cell compartment (4) . To assess the frequency of circulating CD4+ CTLs in patients with active, untreated IgG4-RD, we analyzed T EM cells for the expression of SLAMF7. 
EFFECT OF GLUCOCORTICOID TREATMENT ON CD4+ CYTOTOXIC T CELLS IN IgG4-RD
IgG4-RD and healthy subjects was 4,478 cells/ml (range 200-41,960 cells/ml) and 2,989 cells/ml (range 160-20,890 cells/ml), respectively (P > 0.05). Circulating CD8a low CD4+SLAMF7+ T EM cells in patients with active IgG4-RD and healthy subjects represented a median of 3.9% (range 0.4-18.5%) and 3.7% (range 0.1-26%) of T EM cells, respectively (P > 0.05) (Figures 2A and C) .
Great variability in the frequency of circulating CD8a low CD4+SLAMF7+ T EM cells was observed both in IgG4-RD patients and in healthy individuals. Indeed, while circulating CD8aÀCD4+SLAMF7+ T EM cells were uniformly expanded in IgG4-RD patients compared to controls, circulating CD8a low CD4+SLAMF7+ T EM cells were present both in 10 of 18 IgG4-RD patients and in 10 of 18 healthy subjects (56% of each group). Absolute numbers (Figures 2B and D) . Of note, CD8a low CD4+SLAMF7+ T EMRA cells were absent in the Figure 3A) . Granzyme A expression on sorted CD8aÀCD4+SLAMF7+ T EM cells was also confirmed by immunofluorescence ( Figure 3B ). Of note, the expression levels of granzyme A and perforin both on CD8a low and on CD8aÀCD4+SLAMF7+ T EM cells were comparable to those on professional cytotoxic CD8+ T cells ( Figure 3C) . Conversely, the expression of CD8a on CD8a low CD4+SLAMF7+ T EM cells was comparable in IgG4-RD patients and healthy individuals, but significantly lower than that on professional CD8+ T cells ( Figure 3D ).
To gain clues about the involvement of CD8aÀ CD4+ CTLs in IgG4-RD pathogenesis, we profiled the TCR a-and b-chain repertoire in peripheral blood from patients 1 and 5 and looked for shared clones in tissue biopsy samples obtained before treatment at the time of diagnosis. Comprehensive analysis of the TCR a-and bchain nucleotide sequences showed an oligoclonal TCRa/b repertoire of circulating CD8aÀCD4+SLAMF7+ T EM cells and CDR3 clonotypes that were identical to those sequenced within the tissue from each patient (Figures 4A  and B) .
Contraction of clonally expanded CD8aÀCD4+ SLAMF7+ T EM cells following glucocorticoid-induced disease remission. Six months after institution of glucocorticoid treatment, we performed a second flow cytometry analysis to assess the effects of glucocorticoids on CD4+ T EM cells and CD4+SLAMF7+ T EM cells. At that time point, the mean IgG4-RD RI value was 2 (range 1-4), consistent with a clinical improvement in all patients. Fifteen patients had disease in remission, and 3 had achieved a partial response.
The median number of circulating CD4+ T EM cells was 105,672 cells/ml (range 38,501-229,949 cells/ml), representing a median of 23.9% of total CD4+CD45RO+ memory T cells (range 10.6-44.1%), and did not differ from pretreatment level (paired P > 0.05) ( Figures 1A  and B) . Following clinical improvement, the number of circulating CD4+SLAMF7+ T EM cells decreased to a median of 46,585 cells/ml (range 2,304-104,390 cells/ml), and the frequency of these cells decreased to a median of 45.5% of total CD4+ T EM cells (range 28.7-59.9%) (paired P < 0.05 compared to baseline values) ( Figure 2C ). The mean percentage decline of circulating SLAMF7-expressing CD4+ T EM cells from pretreatment level was 19%.
Among CD4+SLAMF7+ T EM cells, the counts of CD8aÀ lymphocytes decreased selectively and reached levels comparable to those in healthy individuals following clinical improvement ( Figure 3C ). In particular, circulating CD8aÀCD4+SLAMF7+ CTLs decreased to a median of 42.8% of total CD4+ T EM cells (range 28.2-50.4%) (paired P = 0.001 compared to baseline value) ( Figure 2C ). The mean percentage decline of circulating CD8aÀCD4+ SLAMF7+ CTLs compared to pretreatment level was 28%. CD8a low CD4+SLAMF7+ T EM cells were not affected by glucocorticoid treatment ( Figure 2C ). Therefore, the reduction of CD4+SLAMF7+ T EM cells after glucocorticoid treatment was mainly due to the selective decrease of the CD8aÀ subset of CD4+SLAMF7+ T EM cells ( Figure 4C) . In a single patient in whom the analysis was performed, the TCRa/b chain repertoire of CD8aÀCD4+SLAMF7+ CTLs showed a decrease in the frequency of the initially expanded clones, corresponding to an increase in the repertoire diversity ( Figure 4A ). No significant effect of glucocorticoids was observed on the T EMRA cell compartment.
DISCUSSION
The concept of cytotoxicity associated with CD4+ Th lymphocytes has steadily emerged in recent years, in contrast with the traditional view of CTLs originating only from major histocompatibility complex (MHC) class Irestricted CD8+ T lymphocytes. CD4+ CTLs, which represent uncommon subsets of highly differentiated CD4+ T EM and CD4+ T EMRA lymphocytes that retain the ability to kill target cells in an MHC class II-dependent manner, arise in response to repeated antigen stimulation (24, 25) . In particular, CD4+ CTLs have been extensively characterized in the setting of chronic viral infections such as cytomegalovirus, dengue, HIV, and hepatitis B and hepatitis C viruses, where they likely complement CD8+ and natural killer T cell immune responses (26) (27) (28) . These cells appear to be of particular importance and superior to CD8+ cytotoxic T cells in maintaining viral latency (29) . CD4+ CTLs have also been identified in autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, and systemic sclerosis, indicating that they might contribute to chronic inflammation and fibrosis as well (24, 25, 30) .
More recently, we contributed to the identification of CD4+ CTLs in the increasingly recognized fibroinflammatory condition IgG4-RD, and we further characterized them as SLAMF7-expressing cells within the CD4+ T EM cell compartment (4). Indeed, SLAMF7+CD4+ T EM cells exhibited distinctive features of CD8+ CTLs, such as 1) expression of the surface antigen CD8a, 2) expression of the transcription factors eomesodermin and RUNX-3, 3) secretion of the cytolytic molecules granzyme A and perforin, and 4) in vitro cytotoxic activity (4).
Herein we describe for the first time the effects of glucocorticoids on CD4+ CTLs, and we demonstrate that the expression of CD8a identifies at least 2 distinct subsets of CD4+SLAMF7+ CTLs within the T EM and T EMRA cell compartments of patients with IgG4-RD. CD8aÀ but not CD8a low CD4+SLAMF7+ T EM CTLs correlate with IgG4-RD activity, since the former, in contrast to the latter, are increased in the peripheral blood of patients with active, untreated disease, express TCR clones also found in affected lesions, and appear to be selectively modulated with disease remission after glucocorticoid treatment. Indeed, the finding of common CDR3 sequences expressed by dominant circulating CD8aÀCD4+SLAMF7+ CTL clones and tissue-infiltrating lymphocytes strongly supports a pathophysiologic relevance of these cells in IgG4-RD, because it indicates that antigen-specific cytotoxic T cells activated in secondary lymphoid organs are directly present at the site of active disease. In this sense, CD8aÀCD4+SLAMF7+ CTLs might represent the intralesional SLAMF7+CD4+ granzyme A-positive T cells that have been previously shown to infiltrate tissues in patients with IgG4-RD, although further studies are warranted to address this issue (5) . Definitive confirmation of this finding would require TCR repertoire analysis on CD8aÀCD4+SLAMF7+ CTLs sorted directly from fresh IgG4-RD biopsy samples.
The response of CD8aÀCD4+SLAMF7+ T EM cells to glucocorticoids also represents an important finding above and beyond the previously reported effect of rituximab on CD4+SLAMF7+ CTLs in patients with IgG4-RD (4). By depleting CD20+ naive B cells, rituximab is presumed to deprive activated CD4+ T lymphocytes of B cell-derived survival signals, thus limiting the expansion of both pathogenic and bystander T cell clones (11, 12) . Accordingly, the decreased CD4+SLAMF7+ CTL counts that we previously observed in IgG4-RD patients treated with rituximab might have been a general consequence of B cell depletion on activated CD4+ T cells. Conversely, glucocorticoids have minimal long-term effects on circulating CD19+ and CD20+ B cells in IgG4-RD patients, which offers a different perspective for identifying alterations of putatively pathogenic cells eventually associated with disease remission (Lanzillotta M, et al: unpublished observations). Therefore, the selective decrease of CD8aÀCD4+SLAMF7+ CTLs but not of CD8a low CD4+SLAMF7+ CTLs induced by glucocorticoid treatment further strengthens the pathogenic link between CD8aÀCD4+SLAMF7+ CTLs and IgG4-RD and unveils a potentially relevant mechanism behind the efficacy of glucocorticoids in patients with this condition. The reduced frequency of expanded CD8aÀCD4+SLAMF7+ T cell clones that we observed in a single patient after glucocorticoid treatment also supports the hypothesis of a contraction of antigen-specific T lymphocytes but deserves additional confirmation in a larger number of patients.
On the other hand, CD8a low CD4+ CTLs represented a minor population within the expanded CD4+ SLAMF7+ T EM cell pool in IgG4-RD patients, and these could also be found in healthy individuals, which is inconsistent with a causal role in IgG4-RD inflammation and fibrosis. In particular, while circulating CD8aÀCD4+ SLAMF7+ T EM cells appeared to be uniformly expanded only in patients with active IgG4-RD, CD8a low CD4+ SLAMF7+ T cells were detectable in 50-60% of both patients and controls. Therefore, these results suggest that CD8a low CD4+ CTLs may not be linked to active IgG4-RD per se but may reflect an underlying chronic disease or preexisting immune responses to common chronic viral infections (e.g., cytomegalovirus and hepatitis B or hepatitis C viruses), as occurs in otherwise healthy subjects. Activation assays with viral peptides would be necessary to confirm this hypothesis and to address the antigen specificity of CD8a low compared to CD8aÀCD4+ SLAMF7+ T EM cells.
In conclusion, we report for the first time that glucocorticoid-induced remission in patients with IgG4-RD is associated with a decrease of circulating CD4+ CTLs, a recently identified potentially pathogenic population of T lymphocytes. Moreover, we identify a CD8aÀ subpopulation of CD4+SLAMF7+ CTLs that has a stronger association with IgG4-RD, as it is selectively depleted by glucocorticoids. Additional studies are needed to address the biologic relationship between CD8aÀCD4+SLAMF7+ T EM and T EMRA cells in IgG4-RD, to functionally characterize them, and to understand the pathogenic relevance of concomitant chronic viral infections in patients with IgG4-RD.
